Key takeaways
Triumeq (abacavir/dolutegravir/lamivudine) and Tivicay (dolutegravir) are both used to treat HIV, but they have some key differences. Triumeq is a combination of three medications: abacavir, dolutegravir, and lamivudine, while Tivicay contains only dolutegravir. Triumeq is a complete HIV regimen, but it requires a genetic test before starting due to the risk of a serious allergic reaction. Tivicay, on the other hand, is used as part of a combination therapy for HIV. Triumeq is taken once daily and is suitable for adults and children weighing at least 13 pounds, whereas Tivicay can be taken once or twice daily and is adults and children weighing at least 66 pounds. Both medications can cause side effects like trouble sleeping and headaches, but Triumeq has additional risks such as severe allergic reactions and liver problems. Lastly, Triumeq is not recommended for people with severe liver issues, and Tivicay should not be taken with dofetilide due to the risk of serious side effects.
